News Updates
Scope

Wed, May 27, 2026

1 updates
AIM
8:47 AM

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Investor “Ebola: What This Means” Segment on June 4 th at 9:00 AM ET OCALA, Fla., May 27, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American:...

aimimmuno.com

Wed, May 20, 2026

1 updates
AIM
3:02 PM

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the “Common Stock”) (or common...

aimimmuno.com

Tue, May 19, 2026

1 updates

Thu, May 14, 2026

1 updates
AIM
8:41 AM

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consultant for AIM ImmunoTech, is now available on demand here OCALA, Fla., May 14, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc....

Interim Data • Phase 2Interim data Thu, May 14, 2026aimimmuno.com

Fri, May 8, 2026

1 updates
AIM
8:40 AM

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class...

aimimmuno.com

Thu, May 7, 2026

1 updates

Thu, Apr 16, 2026

1 updates

Mon, Apr 13, 2026

1 updates
AIM
6:00 PM

AIM ImmunoTech Provides Routine Update on Annual Filings

OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025, contained an audit report from its independent registered public accounting firm with a going concern emphasis of matter....

aimimmuno.com

Thu, Apr 9, 2026

1 updates
AIM
8:00 AM

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16 th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K....

aimimmuno.com

Wed, Mar 18, 2026

1 updates

Fri, Mar 6, 2026

1 updates
AIM
7:00 PM

AIM ImmunoTech Announces Closing of its Rights Offering

OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today...

aimimmuno.com